Upshot24 Sep 2020 13:08
I suppose the upshot of all this is that we now, at the very least, have an upfront payment (albeit probably small) that offsets against the defaulted Chinese payment. It sounds like this gives Oxilio 6 months in which they alone can choose to do something with NXP001 or not.
If they decide to exercise the option then we get another "significant" upfront payment with possibility of further development milestones and then, if all works, up to 2m in royalties per annum.
Its not blockbuster stuff. However, by taking a chunk of money up front rather than as % royalties, we are basically minimising risk at the expense of later reward. My guess is that Oxilio are a small outfit and so they won't be paying out huge sums at this stage.
The real question here whether the exclusivity clause applies to the option exercise alone or the use of NXP001 overall. This will determine whether or not we can use NXP001 in the future for other deals.
This deal is probably just a means to an end which may enable NFX to progress the other products hopefully further without damaging dilution.